Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Navigating Amorphous Calcium Carbonate Therapies: Eden Ben from Amorphical in Conversation with PharmaShots 

Shots: ACC therapies introduce a novel treatment approach by modulating local pH, promoting bone remodeling, and reducing inflammation, with potential applications in osteoarthritis, calcium deficiencies, late-stage cancers, and bone disorders. Amorphical’s AMOR-18 showed encouraging results in an interim Phase II clinical trial involving COVID-19 patients. PharmaShots speaks with Eden Ben, CEO of Amorphical, to discuss…
September 22, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Sep 15, 2025 – Sep 19, 2025)   

PharmaShots Weekly Snapshots (Sep 15, 2025 – Sep 19, 2025)   This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, COVID-19, M&A and Biosimilars. Check out our full report below:   MAIA Biotechnology Reports P-II (THIO-101) Trial Data of Ateganosine Regimen for Advanced NSCLC Read More: MAIA Biotechnology Akeso Reports First…
September 19, 2025

Read more

TOP 20

Top 20 Monoclonal Antibodies of 2025 

Shots: Redefining treatment paradigms, monoclonal antibody therapies utilize advanced mechanisms of action to provide care across multiple therapeutic areas As of 2024, the global monoclonal antibody therapy market was valued at $252.6B and is projected to reach $497.5B by 2029, growing at a CAGR of 14.5%. Keytruda leads the market with $29.48B in revenue, followed…
September 18, 2025

Read more

VIEWPOINTS

Pain Management & Beyond: Paul Howe from Protega Pharmaceuticals in a Stimulating Conversation with PharmaShots 

Shots: Abuse-deterrent products are prescription medications, primarily opioids and certain stimulants, designed to resist common methods of misuse, such as crushing, snorting, or injecting Protega Pharmaceuticals’ RoxyBond is the first and only FDA-approved, immediate-release abuse-deterrent opioid indicated for managing severe pain when alternative treatments are inadequate PharmaShots is pleased to feature Paul Howe, Chief Operations…
September 17, 2025

Read more

THOUGHTSPOT

Collagen Supplements: Why Choosing the Right Collagen Manufacturer Matters for Your Brand

The rise of collagen supplements in wellness and beauty sectors underscores the importance of selecting the right collagen manufacturer. As consumers demand effective and trustworthy products, the choice of a manufacturer becomes a pivotal factor in brand success and consumer trust. This article delves into why choosing the right collagen manufacturer is essential for building…
September 16, 2025

Read more

Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots
VIEWPOINTS

Wearable Drug Delivery System: Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots 

Shots: Enable Injections recently shared survey findings indicating that many oncology assets with strong commercial potential are often prematurely abandoned or deprioritized due to challenges in formulating small volumes (<3 mL) for subcutaneous delivery. To address this need, Enable Injections developed enFuse, an innovative, hands-free, wearable drug delivery platform with a discreet, hidden needle that…
September 15, 2025

Read more

Innovative Minds Psychedelics in Medicine
MAGAZINE

PharmaShots Magazine-September-2025 Edition

Medical psychedelics are a fascinating field that modern science has yet to comprehend completely. Researchers are still digging up, trying to find evidence-based outcomes to tap into a whole new opportunity in psychiatry and mental health medicinesThe September Edition unearths a brand-new perspective on psychedelics through engaging articles, illustrative infographics, trailing BioTrends, illuminating regulatory…
September 11, 2025

Read more

Load more